Detection of HIV-1 dual infections in highly exposed treated patients

Virology Journal

Volumn 8, Issue , 2011, Pages

  Andreani, Guadalupe ^a   Espada, Constanza ^a   Ceballos, Ana ^a   Ambrosioni, Juan ^a   Petroni, Alejandro ^b   Pugliese, Dora ^b   Bouzas, María Belén ^c   Fernandez Giuliano, Silvia ^c   Weissenbacher, Mercedes C ^a   Losso, Marcelo ^d   Benetucci, Jorge ^b   Carr, Jean K ^e   Martínez Peralta, Liliana ^a  

^a UNIVERSIDAD DE BUENOS AIRES   (Argentina)

^b Lab de Retrovirus y Virus Asociados   (Argentina)

^c Infectious Diseases Hospital   (Argentina)

^d HOSPITAL RAMOS MEJÍA   (Argentina)

^e SAINT JAMES SCHOOL OF MEDICINE   (Anguilla)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIRETROVIRUS AGENT; ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT; POL PROTEIN;

ANTIVIRAL SUSCEPTIBILITY; ARGENTINA; ARTICLE; BLOOD SAMPLING; CD4+ T LYMPHOCYTE; CLINICAL ARTICLE; GENE POOL; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INFECTION RISK; MALE; MIXED INFECTION; MUTATIONAL ANALYSIS; PHYLOGENY; REINFECTION; SEQUENCE ANALYSIS; ANTIVIRAL RESISTANCE; BLOOD; CLASSIFICATION; CLUSTER ANALYSIS; DNA SEQUENCE; GENETICS; ISOLATION AND PURIFICATION; MISSENSE MUTATION; POLYMERASE CHAIN REACTION; VIROLOGY;

HUMAN IMMUNODEFICIENCY VIRUS 1;

ANTI-HIV AGENTS; ARGENTINA; BLOOD; CLUSTER ANALYSIS; DRUG RESISTANCE, VIRAL; HIV INFECTIONS; HIV-1; HUMANS; MALE; MUTATION, MISSENSE; PHYLOGENY; POL GENE PRODUCTS, HUMAN IMMUNODEFICIENCY VIRUS; POLYMERASE CHAIN REACTION; SEQUENCE ANALYSIS, DNA;

EID: 79961113618     PISSN: None     EISSN: 1743422X     Source Type: Journal    
DOI: 10.1186/1743-422X-8-392     Document Type: Article

References (22)

1. Identifying HIV-1 dual infections. van der Kuyl AC, Cornelissen M, Retrovirology 2007 4 67 10.1186/1742-4690-4-67 17892568 (Pubitemid 350031738)
2. The probable source of both the primary multidrug-resistant (MDR) HIV-1 strain found in a patient with rapid progression to AIDS and a second recombinant MDR strain found in a chronically HIV-1-infected patient. Blick G, Kagan RM, Coakley E, Petropoulos C, Maroldo L, Greiger-Zanlungo P, Gretz S, Garton T, J Infect Dis 2007 195 1250 1259 10.1086/512240 17396993 (Pubitemid 46649609)
3. A dual superinfection and recombination within HIV-1 subtype B 12 years after primoinfection. Pernas M, Casado C, Fuentes R, Perez-Elias MJ, Lopez-Galindez C, J Acquir Immune Defic Syndr 2006 42 12 18 10.1097/01.qai. 0000214810.65292.73 16763489 (Pubitemid 43947941)
4. HIV drug resistance acquired through superinfection. Smith DM, Wong JK, Hightower GK, Ignacio CC, Koelsch KK, Petropoulos CJ, Richman DD, Little SJ, Aids 2005 19 1251 1256 10.1097/01.aids.0000180095.12276.ac 16052079 (Pubitemid 41224893)
5. Drug induced superinfection in HIV and the evolution of drug resistance. Leontiev VV, Maury WJ, Hadany L, Infect Genet Evol 2008 8 40 50 10.1016/j.meegid.2007.09.008 18024234 (Pubitemid 350215288)
6. Two HIV-1 epidemics in Argentina: different genetic subtypes associated with different risk groups. Avila MM, Pando MA, Carrion G, Peralta LM, Salomon H, Carrillo MG, Sanchez J, Maulen S, Hierholzer J, Marinello M, et al. J Acquir Immune Defic Syndr 2002 29 422 426 11917249 (Pubitemid 34288898)
7. Intersubtype BF recombinants of HIV-1 in a population of injecting drug users in Argentina. Espinosa A, Vignoles M, Carrillo MG, Sheppard H, Donovan R, Peralta LM, Rossi D, Radulich G, Salomon H, Weissenbacher M, J Acquir Immune Defic Syndr 2004 36 630 636 10.1097/00126334-200405010-00012 15097307 (Pubitemid 38544513)
8. Buenos Aires cohort of men who have sex with men: prevalence, incidence, risk factors, and molecular genotyping of HIV type 1. Segura M, Sosa Estani S, Marone R, Bautista CT, Pando MA, Eyzaguirre L, Sanchez JL, Carr JK, Montano SM, Weissenbacher M, Avila MM, AIDS Res Hum Retroviruses 2007 23 1322 1329 10.1089/aid.2007.0063 18184073
9. Outbreak of a West African recombinant of HIV-1 in Tashkent, Uzbekistan. Carr JK, Nadai Y, Eyzaguirre L, Saad MD, Khakimov MM, Yakubov SK, Birx DL, Graham RR, Wolfe ND, Earhart KC, Sanchez JL, J Acquir Immune Defic Syndr 2005 39 570 575 16044009 (Pubitemid 41098472)
10. Update on Primary HIV-1 Resistance in Argentina: Emergence of Mutations Conferring High-Level Resistance to Nonnucleoside Reverse Transcriptase Inhibitors in Drug-Naive Patients. Petroni AD, Gabriel, Pryluka D, Rotryng F, Bortolozzi R, Lopardo G, Bouzas MB, Zapiola I, Garone D, Rodríguez C, Chiocconi E, Lázaro ME, Murano F, Maranzana A, Oliva SM, Aparicio M, Beltrán M, Benetucci J, JAIDS 2006 42 506 510 10.1097/01.qai.0000222285. 44460.e2 16773027 (Pubitemid 44050902)
11. Differences in frequencies of drug resistance-associated mutations in the HIV-1 pol gene of B subtype and BF intersubtype recombinant samples. Carobene MG, Rubio AE, Carrillo MG, Maligne GE, Kijak GH, Quarleri JF, Salomon H, J Acquir Immune Defic Syndr 2004 35 207 209 10.1097/00126334-200402010-00018 14722457 (Pubitemid 38133748)
12. HIV type 1 fitness evolution in antiretroviral-experienced patients with sustained CD4+ T cell counts but persistent virologic failure. Prado JG, Parkin NT, Clotet B, Ruiz L, Martinez-Picado J, Clin Infect Dis 2005 41 729 737 10.1086/432619 16080097 (Pubitemid 41170363)
13. The M184V mutation: what it does, how to prevent it, and what to do with it when it's there. Gallant JE, AIDS Read 2006 16 556 559 17096474 (Pubitemid 44646033)
14. Update of the drug resistance mutations in HIV-1: December 2009. Johnson VA, Brun-Vezinet F, Clotet B, Gunthard HF, Kuritzkes DR, Pillay D, Schapiro JM, Richman DD, Top HIV Med 2009 17 138 145 20068260
15. In vivo fitness cost of the M184V mutation in multidrug-resistant human immunodeficiency virus type 1 in the absence of lamivudine. Paredes R, Sagar M, Marconi VC, Hoh R, Martin JN, Parkin NT, Petropoulos CJ, Deeks SG, Kuritzkes DR, J Virol 2009 83 2038 2043 10.1128/JVI.02154-08 19019971
16. Different evolutionary patterns are found within human immunodeficiency virus type 1-infected patients. Casado C, Garcia S, Rodriguez C, del Romero J, Bello G, Lopez-Galindez C, J Gen Virol 2001 82 2495 2508 11562542 (Pubitemid 32936782)
17. Intersubtype human immunodeficiency virus type 1 superinfection following seroconversion to primary infection in two injection drug users. Ramos A, Hu DJ, Nguyen L, Phan KO, Vanichseni S, Promadej N, Choopanya K, Callahan M, Young NL, McNicholl J, et al. J Virol 2002 76 7444 7452 10.1128/JVI.76.15.7444-7452. 2002 12097556 (Pubitemid 34760966)
18. Chronic HIV-1 infection frequently fails to protect against superinfection. Piantadosi A, Chohan B, Chohan V, McClelland RS, Overbaugh J, PLoS Pathog 2007 3 177 10.1371/journal.ppat.0030177 18020705 (Pubitemid 350291609)
19. Recombination following superinfection by HIV-1. Fang G, Weiser B, Kuiken C, Philpott SM, Rowland-Jones S, Plummer F, Kimani J, Shi B, Kaul R, Bwayo J, et al. Aids 2004 18 153 159 10.1097/00002030-200401230-00003 15075531 (Pubitemid 38253436)
20. A sudden rise in viral load is infrequently associated with HIV-1 superinfection. Jurriaans S, Kozaczynska K, Zorgdrager F, Steingrover R, Prins JM, van der Kuyl AC, Cornelissen M, J Acquir Immune Defic Syndr 2008 47 69 73 10.1097/QAI.0b013e3181582d6f 17891042 (Pubitemid 351619371)
21. HIV superinfection in the era of increased sexual risk-taking. Blackard JT, Mayer KH, Sex Transm Dis 2004 31 201 204 10.1097/01.OLQ.0000118082.45312.1F 15028931 (Pubitemid 38401915)
22. HIV diversity, molecular epidemiology, and the role of recombination. Kijak GH, McCutchan FE, Curr Infect Dis Rep 2005 7 480 488 10.1007/s11908-005- 0051-8 16225787 (Pubitemid 41671592)